Deciphering the Roles of Thiazolidinediones and PPARγ in Bladder Cancer
Melody Chiu1, Lucien McBeth1, Puneet Sindhwani2
1Center for Hypertension and Personalized Medicine, Department of Physiology & Pharmacology, University of Toledo College of Medicine, Toledo, OH 43614, USA.
Abstract:
The use of thiazolidinedione (TZD) therapy in type II diabetic patients has proven useful in the lowering of blood glucose levels. However, recent investigations have shown that there may be potential health concerns associated, including the risk of developing bladder cancer as well as complications in the cardiovasculature. TZDs are ligands for the nuclear receptor PPARγ, and activation causes lipid uptake and insulin sensitization, both of which are critical processes for diabetic patients whose bodies are unable to utilize insulin effectively. Several studies have shown that PPARγ/TZDs decrease IGF-1 levels and, thus, reduce cancer growth in carcinomas such as the pancreas, colon, liver, and prostate. However, other studies have shed light on the potential of the receptor as a biomarker for uroepithelial carcinomas, particularly due to its stimulatory effect on migration of bladder cancer cells. Furthermore, PPARγ may provide the tumor-promoting microenvironment by de novo synthesis of nutrients that are needed for bladder cancer development. In this review, we closely examine the TZD class of drugs and their effects on PPARγ in patient studies along with additional molecular factors that are positive modulators, such as protein phosphatase 5 (PP5), which may have considerable implications for bladder cancer therapy.
Insights
Thiazolidinediones (TZDs) manage blood glucose but may increase bladder cancer risk by affecting the PPARγ receptor. This review explores TZDs, PPARγ, and their complex role in bladder cancer development and therapy.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Thiazolidinediones (TZDs) are used to treat type II diabetes by improving insulin sensitivity via PPARγ activation.
- While effective for glycemic control, TZDs have been linked to potential cardiovascular risks and an increased risk of bladder cancer.
- The nuclear receptor PPARγ plays a dual role in cancer, inhibiting some carcinomas but potentially promoting uroepithelial cancers.
Purpose of the Study:
- To review the effects of thiazolidinedione (TZD) therapy on the nuclear receptor PPARγ.
- To examine the complex role of PPARγ in the context of bladder cancer.
- To discuss implications for bladder cancer therapy, considering modulators like protein phosphatase 5 (PP5).
Main Methods:
- Review of existing patient studies on TZD therapy and PPARγ.
- Analysis of molecular mechanisms linking PPARγ activation to cancer cell behavior.
- Examination of factors that modulate PPARγ activity in cancer.
Main Results:
- TZDs activate PPARγ, leading to insulin sensitization and lipid uptake.
- PPARγ activation by TZDs has been shown to reduce growth in several cancer types (pancreatic, colon, liver, prostate) by decreasing IGF-1 levels.
- Conversely, PPARγ may act as a biomarker for uroepithelial carcinomas, promoting bladder cancer cell migration and creating a tumor-promoting microenvironment.
Conclusions:
- The role of PPARγ in cancer is context-dependent, with significant implications for bladder cancer.
- TZD therapy's impact on PPARγ presents a complex therapeutic challenge in diabetic patients with or at risk for bladder cancer.
- Further research into PPARγ modulators like PP5 is crucial for developing targeted bladder cancer therapies.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
01:23Dipeptidyl Peptidase 4 Inhibitors
02:23Abnormal Proliferation